← Eichor
Study identifier: NCT07130773 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters

Condition: Atrial Fibrillation (AF) · Atrial Fibrillation Ablation · Pulsed Field Ablation  ·  Sponsor: Cardiocentro Ticino

PhaseNA
Planned participants58
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow. The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure. Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free …

This description comes directly from the study's public registry record.

Talk to the study team

Marco Bergonti, MD PhD  ·  +41 (0) 91 811 51 11  ·  bergmar21@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cardiocentro Ticino - Ente Ospedaliero CantonaleLugano, Canton Ticino, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07130773